BNP Paribas Financial Markets’s Denali Therapeutics DNLI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $645K | Sell |
25,071
-14,822
| -37% | -$305K | ﹤0.01% | 3619 |
|
|
2026
Q1 | $766K | Buy |
39,893
+24,396
| +157% | +$485K | ﹤0.01% | 3324 |
|
|
2025
Q4 | $256K | Sell |
15,497
-248,564
| -94% | -$4.2M | ﹤0.01% | 3941 |
|
|
2025
Q3 | $3.83M | Buy |
264,061
+244,979
| +1,284% | +$3.52M | ﹤0.01% | 2161 |
|
|
2025
Q2 | $267K | Buy |
19,082
+10,367
| +119% | +$146K | ﹤0.01% | 3667 |
|
|
2025
Q1 | $118K | Sell |
8,715
-7,228
| -45% | -$138K | ﹤0.01% | 3977 |
|
|
2024
Q4 | $325K | Sell |
15,943
-11,682
| -42% | -$299K | ﹤0.01% | 3577 |
|
|
2024
Q3 | $805K | Buy |
27,625
+19,259
| +230% | +$477K | ﹤0.01% | 2611 |
|
|
2024
Q2 | $194K | Sell |
8,366
-63,739
| -88% | -$1.22M | ﹤0.01% | 3113 |
|
|
2024
Q1 | $1.48M | Sell |
72,105
-119,538
| -62% | -$2.25M | ﹤0.01% | 2247 |
|
|
2023
Q4 | $4.11M | Buy |
191,643
+28,817
| +18% | +$571K | ﹤0.01% | 1536 |
|
|
2023
Q3 | $3.36M | Buy |
162,826
+55,344
| +51% | +$1.4M | ﹤0.01% | 1547 |
|
|
2023
Q2 | $3.17M | Sell |
107,482
-30,590
| -22% | -$860K | ﹤0.01% | 1483 |
|
|
2023
Q1 | $3.18M | Buy |
138,072
+80,384
| +139% | +$2.21M | ﹤0.01% | 1526 |
|
|
2022
Q4 | $1.6M | Sell |
57,688
-50,881
| -47% | -$1.51M | ﹤0.01% | 1887 |
|
|
2022
Q3 | $3.33M | Buy |
108,569
+86,237
| +386% | +$2.8M | 0.01% | 1593 |
|
|
2022
Q2 | $657K | Buy |
22,332
+14,089
| +171% | +$369K | ﹤0.01% | 2504 |
|
|
2022
Q1 | $265K | Sell |
8,243
-11,456
| -58% | -$394K | ﹤0.01% | 3032 |
|
|
2021
Q4 | $879K | Buy |
19,699
+1,700
| +9% | +$80.5K | ﹤0.01% | 2683 |
|
|
2021
Q3 | $908K | Buy |
17,999
+11,951
| +198% | +$674K | ﹤0.01% | 2430 |
|
|
2021
Q2 | $474K | Sell |
6,048
-4,854
| -45% | -$300K | ﹤0.01% | 2558 |
|
|
2021
Q1 | $623K | Buy |
10,902
+1,006
| +10% | +$67.3K | ﹤0.01% | 2444 |
|
|
2020
Q4 | $829K | Sell |
9,896
-5,006
| -34% | -$303K | ﹤0.01% | 2145 |
|
|
2020
Q3 | $534K | Buy |
14,902
+8,303
| +126% | +$250K | ﹤0.01% | 2182 |
|
|
2020
Q2 | $160K | Sell |
6,599
-15,982
| -71% | -$376K | ﹤0.01% | 2582 |
|
|
2020
Q1 | $395K | Buy |
22,581
+15,502
| +219% | +$323K | ﹤0.01% | 2476 |
|
|
2019
Q4 | $123K | Sell |
7,079
-1,699
| -19% | -$28.3K | ﹤0.01% | 3190 |
|
|
2019
Q3 | $134K | Buy |
8,778
+2,266
| +35% | +$43.3K | ﹤0.01% | 2954 |
|
|
2019
Q2 | $135K | Sell |
6,512
-4,144
| -39% | -$92.9K | ﹤0.01% | 2852 |
|
|
2019
Q1 | $247K | Buy |
10,656
+9,470
| +798% | +$198K | ﹤0.01% | 2572 |
|
|
2018
Q4 | $24.5K | Sell |
1,186
-602
| -34% | -$10.9K | ﹤0.01% | 3031 |
|
|
2018
Q3 | $38.9K | Buy |
1,788
+537
| +43% | +$8.88K | ﹤0.01% | 3153 |
|
|
2018
Q2 | $19.1K | Sell |
1,251
-1,813
| -59% | -$34.2K | ﹤0.01% | 3516 |
|
|
2018
Q1 | $60.3K | Buy |
+3,064
| New | +$63K | ﹤0.01% | 3463 |
|
Other funds holding DNLI
BBA
BNP Paribas Financial Markets's DNLI Position: Q2 2026 in Review
BNP Paribas Financial Markets reduced its Denali Therapeutics (DNLI) stake by 37% in Q2 2026, selling an estimated $305K and leaving 25,071 shares worth $645K. The position accounts for ﹤0.01% of the portfolio, ranked #3619.
BNP Paribas Financial Markets first reported a position in DNLI in Q1 2018 and has held it in 34 quarters since. The position peaked at $4.11M in Q4 2023. 273 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.
- BNP Paribas Financial Markets held 25,071 shares of Denali Therapeutics worth $645K as of Q2 2026.
- BNP Paribas Financial Markets sold 14,822 Denali Therapeutics shares in Q2 2026, an estimated $305K.
- Denali Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #3619 holding.
- BNP Paribas Financial Markets first reported a position in Denali Therapeutics in Q1 2018 and has held it in 34 quarters since.
- BNP Paribas Financial Markets's Denali Therapeutics position peaked at $4.11M in Q4 2023.
- 273 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.
Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.